Platinum-Resistant Ovarian Carcinoma — Trials

Platinum-Resistant Ovarian Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

109 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 56
Recruiting: 29
Ph III recruiting: 3
Growth YoY: —
Industry share: 48%
Top sponsor: National Cancer Institute (NCI)
Termination share: 52.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	recruiting	Phase 2	80	Roswell Park Cancer InstituteOTHER	1	Aug 14, 2026	clinicaltrials
NCT05579366	Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01)	recruiting	Phase 1 / Phase 2	884	GenmabINDUSTRY	3	Aug 4, 2026